CDKN2A and astrocytoma (excluding glioblastoma): Although the overall prognostic significance is still controversial [37], a large-scale study demonstrated that in addition to CDKN2A/B deletion, CDK4 amplification, which also deregulates Rb pathway, was associated with poor prognosis in IDH-mutant astrocytoma [3, 27].